These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18050723)

  • 21. [Urology].
    Jichlinski P; Wisard M
    Rev Med Suisse; 2009 Jan; 5(186):144-6. PubMed ID: 19238935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
    Bratt O; Björk T
    Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
    [No Abstract]   [Full Text] [Related]  

  • 23. Pitfalls or promise in prostate cancer immunotherapy-which is winning?
    Slovin SF
    Cancer J; 2008; 14(1):26-34. PubMed ID: 18303480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in chromatin phenotype predict the response to hormonal deprivation therapy in patients with prostate cancer.
    Mohamed M; Greif PA; Diamond J; Sharafeldin O; Maxwell P; Montironi R; O'Brien A; Young M; Hamilton PW
    BJU Int; 2009 Feb; 103(3):391-8. PubMed ID: 19021609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
    Hussein MR; Al-Assiri M; Musalam AO
    Exp Mol Pathol; 2009 Apr; 86(2):108-13. PubMed ID: 19111537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urologic Clinics of North America. Castrate-resistant prostate cancer. Foreword.
    Taneja SS
    Urol Clin North Am; 2012 Nov; 39(4):xiii. PubMed ID: 23084534
    [No Abstract]   [Full Text] [Related]  

  • 30. Urologic Clinics of North America. Castrate-resistant prostate cancer. Preface.
    Kibel AS
    Urol Clin North Am; 2012 Nov; 39(4):xv. PubMed ID: 23084535
    [No Abstract]   [Full Text] [Related]  

  • 31. How to define hormone-resistance.
    de Voogt HJ; Rao RB; Geldof AA
    Prog Clin Biol Res; 1989; 303():325-9. PubMed ID: 2780653
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
    J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do we continue hormonal treatment after hormone resistance?
    Jones WG
    Prog Clin Biol Res; 1989; 303():331-6. PubMed ID: 2674994
    [No Abstract]   [Full Text] [Related]  

  • 34. Commentary: how serious is getting a diagnosis of prostate cancer?
    Barry MJ
    Oncologist; 2008 Mar; 13(3):306-8. PubMed ID: 18378541
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
    Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
    Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined radiation and hormonal therapy or dose escalation for men with unfavourable-risk prostate cancer: an evidence-based approach using a synthesis of randomized clinical trials.
    Nanda A; D'Amico AV
    BJU Int; 2008 Nov; 102(10):1366-8. PubMed ID: 18778343
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: B.J. De Castro and K. C. Baker: Effect of flexible cystoscopy on serum prostate-specific antigen values (Urology 2009; 73:237-240).
    Romics I
    Urology; 2009 Jul; 74(1):234. PubMed ID: 19567303
    [No Abstract]   [Full Text] [Related]  

  • 39. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 40. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation.
    Uhlin M; Okas M; Karlsson H; Gertow J; Henningsohn L; Ringdén O; Kärre K; Levitsky V; Mattsson J
    Transplantation; 2009 Feb; 87(4):467-72. PubMed ID: 19307781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.